AstraZeneca PLC (FRA:ZEG)
Germany
· Delayed Price · Currency is EUR | Market Cap | 191.32B |
| Revenue (ttm) | 50.87B |
| Net Income (ttm) | 7.19B |
| Shares Out | n/a |
| EPS (ttm) | 4.60 |
| PE Ratio | 26.61 |
| Forward PE | 15.51 |
| Dividend | 2.93 (2.44%) |
| Ex-Dividend Date | Feb 20, 2025 |
| Volume | 10,269 |
| Average Volume | 11,822 |
| Open | 119.75 |
| Previous Close | 119.55 |
| Day's Range | 119.20 - 120.80 |
| 52-Week Range | 111.00 - 158.20 |
| Beta | n/a |
| RSI | 34.89 |
| Earnings Date | Jul 29, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
Onco-Innovations Welcomes AstraZeneca's Interest in Founding Role in PROmAI - an Inka-led AI-Oncology Consortium
VANCOUVER, BC / ACCESS Newswire / June 27, 2025 / Onco-Innovations Limited(CBOE CA:ONCO)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly-owned subsidiary, I...
Man’s Best Friend review – lockdown, loneliness and a pack of cute canines
Tron theatre, Glasgow Douglas Maxwell’s monologue about a dog walker moves from lighthearted to maudlin as it evokes a world in limbo A few blocks down the road on Argyle Street, a stall is promoting ...
AstraZeneca invests Rs 166 crore to expand Bengaluru operations
Bengaluru: Global biopharmaceutical company AstraZeneca is investing Rs166 crore to expand its Bengaluru operations, creating 400 new jobs. The upgrad.
Daiichi Sankyo, AstraZeneca gets U.S. approval for Datroway
AstraZeneca's Datroway Approved to Treat Non-Small Cell Lung Cancer in U.S.
The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a Phase 2 trial. The approval was also supported by data from a Phase 3 trial...
US approves AstraZeneca, Daiichi's treatment for lung cancer
AstraZeneca said on Tuesday that U.S. regulators have approved its precision drug Datroway to treat a type of lung cancer, adding that the drugmaker would now pay partner Daiichi Sankyo $45 million in...
DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Based on TROPION-Lung05 phase 2 trial results and supported by data from the TROPION-Lung01 phase 3 trial Second U.S. approval for Daiichi Sankyo and AstraZeneca's DATROWAY in less than six months DAT...
Is the Market Bullish or Bearish on AstraZeneca?
AstraZeneca's (NYSE: AZN) short percent of float has fallen 8.33% since its last report. The company recently reported that it has 6.92 million shares sold short , which is 0.22% of all regular share...
Targeted cancer drugs may replace chemo for some patients and drugmakers say they're getting closer
Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve their efficacy and safety.
5 Ideal 'Safer' Dividend Buys From Bloomberg's June Watch List
I highlight 15 dividend-paying stocks from Bloomberg's 50 Companies to Watch that meet my 'safer' criteria: free cash flow yields exceed dividend yields. The top ten dividend focus stocks offer an est...
AstraZeneca in deal with China firm worth up to £4bn
Astra has agreed a deal that could be worth almost £4billion with a Chinese company to use AI in the production of new treatments for chronic diseases.
AstraZeneca Inks China AI Research Deal For Chronic Diseases
British drugmaker AstraZeneca unveiled on Friday an AI-assisted research partnership with Chinese counterpart CSPC Pharmaceuticals worth up to $5.3 billion to tackle chronic diseases.
AstraZeneca signs research agreement with China's CSPC
AstraZeneca Inks Research Pact With China's CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 Billion
On Friday, AstraZeneca Plc (NASDAQ: AZN) entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited . Per the agreement, AstraZeneca and CSPC agree to ...
AstraZeneca signs $5.2bn deal to develop drugs for chronic disease with Chinese biotech
Partnership gives group access to CSPC’s AI platform for discovering and optimising treatments
AstraZeneca signs US$5 billion research deal with China’s CSPC
AstraZeneca has signed a research agreement worth more than US$5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the Anglo-Swedish drugmaker said on Friday.
AstraZeneca Teams Up With CSPC Pharmaceuticals With Deal Valued at Up to $5.33 Billion
The deal with China's CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of new drug candidates.
AstraZeneca agrees to research deal worth up to $5.22 billion with CSPC
AstraZeneca said on Friday it has agreed to a research deal with Chinese drugmaker CSPC Pharmaceuticals worth up to $5.22 billion to focus on AI-enabled initiatives.
I attended the world's biggest cancer conference. Doctors gave standing ovations to 2 major breakthroughs.
Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca is pioneering new ways to treat early disease.
Merck wins FDA nod for RSV shot for infants, challenging Sanofi/ AstraZeneca
What's Going On With IonQ Shares Monday?
IonQ, Inc. (NYSE: IONQ) shares traded higher Monday after the company announced results of a collaborative research program with AstraZeneca PLC (NASDAQ: AZN), Amazon Web Services and NVIDIA Corp (N...
FDA approves Mercks RSV shot for infants, ramping up competition with Sanofi and AstraZeneca
Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer
The first patient has been dosed in the DESTINY-Endometrial01 phase 3 trial evaluating ENHERTU ® (trastuzumab deruxtecan) in combination with rilvegostomig or pembrolizumab versus platinum-based chemo...